In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report). The ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Adaptimmune Therapeutics is prepping for another FDA submission after ... facing a devastating disease with limited ...

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

Cathie Wood's ARK Innovation ETF (ARKK) has surged to its highest trading level in more than two years this week, surpassing ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Canada ordered striking dock workers back to the ports of Vancouver, Prince Rupert and Montreal on Tuesday to clear out more ...

ALT5 Prime is an electronic over-the-counter trading platform ... The Company is working on the separation of our biotech business that will become known as 'Alyea Therapeutics.' Forward Looking ...

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...

A new study in mice explains how even a single faulty copy of the BRCA1 gene can fuel tumor growth. The findings suggest the dominant “two-hit” hypothesis of cancer development may not tell the full ...